Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.

Latest From Cathy Kelly

Tie Goes To The Nominee: Becerra Heads To Senate Floor

Without Republican support, Biden’s HHS nominee couldn’t get a majority in the Finance Committee, but that shouldn’t imperil his bid to become secretary of Health and Human Services.

Politics Pricing Debate

AstraZeneca/FibroGen’s Roxadustat Comparison To ESAs In Anemia May By Clarified At FDA Advisory Cmte.

Payers would welcome any additional clarity provided by advisory panel review, given the perception, expressed in a recent ICER report, that the evidence is insufficient to determine whether the new drug is safer or more effective than erythropoiesis-stimulating agents.

Advisory Committees Reimbursement

Medicare Drug Pricing Demonstration Agenda May Be Reshaped By Fowler As CMMI Head

Elizabeth Fowler brings combination of Capitol Hill, White House and pharma industry experience to the role of director of the Center for Medicare and Medicaid Innovation.

Medicare Reimbursement

Rebate Proposals Targeting Single-Use Vials May Be Barking Up The Wrong Tree

Policymakers should instead focus on increasing efficiencies in drug development, distribution and reimbursement, National Academies report says, while also seeking broad policies like HHS direct negotiation for drug prices in Medicare.

Pricing Debate Medicare

Drug Pricing Among Range Of Issues Senators Want HHS Nominee Becerra To Work On

Senate Finance confirmation hearing concluded without a vote on Xavier Becerra’s nomination as Health and Human Services Department secretary. Republicans continued to express concerns with his background and views. But he is expected to win enough votes to clear the committee.

Pricing Debate Legislation

HHS Secretary Nominee Becerra Plans ‘Swift’ Action On Drug Pricing Reform

‘We need the pharmaceutical industry … to always feel we’ve got their back to innovate,’ Becerra tells Senate Committee. ‘But we have to ensure that we’re getting our dollars’ worth.’

Pricing Debate Legislation
See All
UsernamePublicRestriction

Register